<DOC>
	<DOCNO>NCT01913964</DOCNO>
	<brief_summary>To assess effect Acetyl-L-Carnitine administration work productivity , daily activity , fatigue subject chronic hepatitis C treat Pegylated-Interferon-α2b Ribavirin .</brief_summary>
	<brief_title>Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>worker 18 year age old Workers infect HCV quantifiable serum HCV RNA level ( determined polimerase chain reaction , COBAS AmpliPrep/COBAS TaqMan ROCHE ) Cirrhotic worker ChildPugh score less 7 worker liver disease cancer severe jaundice pulmonary renal chronic disease , prostatic disease autoimmune disease diabetes mellitus decompensated cirrhosis pregnancy cardiopathy hemoglobinopathy hemocromatosis major depression severe psychiatric pathological condition</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>